Sanofi bouwt eigen AI-systeem om voorsprong op concurrenten te behalen

Sanofi is developing its own artificial intelligence infrastructure rather than relying on existing commercial tools. The French pharmaceutical company rejected licensing ChatGPT and limited Microsoft Copilot access after finding these solutions inadequate for its specific needs.